Publication | Open Access

Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors

Acquired ResistanceMedicinePharmacologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung Cancer